

ForPatients

by Roche

Multiple Sclerosis (MS) Primary Progressive Multiple Sclerosis (PPMS)

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Trial Status
Completed

Trial Runs In
29 Countries

Trial Identifier
NCT01194570 2010-020338-25
WA25046

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT01194570 2010-020338-25 WA25046
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 55 Years

Healthy Volunteers
No
